Evidence map›Paper›PMID 24859274›Full record

Trial reportPloS one2014

Decreased expression of CXCR4 chemokine receptor in bone marrow after chemotherapy in patients with non-Hodgkin lymphomas is a good prognostic factor.

Grzegorz Mazur, Aleksandra Butrym, Ilona Kryczek, Dorota Dlubek, Emilia Jaskula, Andrzej Lange, Kazimierz Kuliczkowski, Michal Jelen

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Grzegorz MazurDept. of Internal and Occupational Diseases and Hypertension, Wroclaw Medical University, Wroclaw, Poland.
Aleksandra ButrymDept. of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Physiology, Wroclaw Medical University, Wroclaw, Poland.
Ilona KryczekDepartment of Clinical Immunology, L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Dorota DlubekDepartment of Clinical Immunology, L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Emilia JaskulaDepartment of Clinical Immunology, L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Andrzej LangeDepartment of Clinical Immunology, L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Kazimierz KuliczkowskiDept. of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Michal JelenDivision of Pathomorphology and Oncological Cytology, Wroclaw Medical University, Wroclaw, Poland.
Wroclaw Medical University · PLLudwik Hirszfeld Institute of Immunology and Experimental Therapy · PLPolish Academy of Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCXCR4 chemokine receptor is constitutively expressed on normal and malignant B lymphocytes derived from patients with B-cell lymphoproliferative disorders and has a significant role in cell migration to lymph nodes and bone marrow. Non-Hodgkin's lymphomas (NHL) constitute a heterogeneous group of lymphoproliferative diseases, which can localize not only to lymph nodes, but also can migrate to peripheral blood and metastase to other organs, including bone marrow.

aimThe purpose of this study was to determine CXCR4 gene expression in peripheral blood and bone marrow of NHL patients before and after treatment.

methodsSamples of lymphoma lymph nodes, peripheral blood and bone marrow aspirates of patients with B-cell NHL were taken at diagnosis and after chemotherapy. Gene expression was determined by the reverse transcription (RT)-polymerase chain reaction method. Expression was estimated from 0 AU (no amplificate signal) to 3 AU (maximal amplificate signal).

resultsNo significant difference in the level of CXCR4 expression was found in reactive lymph nodes compared to lymphoma samples We observed high level of CXCR4 expression in most patients before treatment: in bone marrow: 3 AU-10 pts, 2 AU-8 pts, 1 AU-2 pts. In peripheral blood: 3 AU-14 pts, 2 AU-4 pts, 1 AU-1 pts, 0 AU-1 pts. After chemotherapy, significant decrease in CXCR4 expression was observed. Bone marrow: 3 AU-5 pts, 2 AU-7 pts, 1 AU-5 pts, 0 AU-3 pts (p = 0.03). Peripheral blood: 3 AU-2 pts, 2 AU-6 pts, 1 AU-10 pts, 0 AU-2 pts (p = 0.0002). There was a good response to treatment in patients with significant decrease of CXCR4 expression in the bone marrow after treatment with 10-fold lower risk of death (p = 0.03).

conclusionsDecrease in CXCR4 expression in the bone marrow of NHL patients after chemotherapy may be a good prognostic factor.

Indexed as

Bone MarrowLymphoma, Non-HodgkinAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBone Marrow NeoplasmsDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm ProteinsCXCR4 protein, humanNeoplasm ProteinsReceptors, CXCR4

Identifiers

PMID24859274
PMCPMC4032278
OpenAlexW1991483223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.